EGFR alterations have been linked to glioblastoma, and tumors previously defined as diffuse grade 2–3 astrocytoma, IDH wildtype are currently considered glioblastomas if they harbor EGFR amplification (5). The gene discussed is IDH2; the disease is glioblastoma.